Phase II trial using combination of TACE and SBRT for unresectable single large HCC: preliminary report

Buckstein, Michael; Kim, E.; Fischman, Alan J.; Facciuto, M.; Sung, M.; Taouli, Bachir; Llovet, J.M.; Schwartz, M.; Rosenzweig, K.

doi:10.1016/s0168-8278(18)30638-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the efforts that have been made in recent decades, the outcomes and prognosis of patients with HCC remain dismal. TACE is a common therapeutic method for patients with intermediate-stage HCC and is of vital importance in alleviate the pathological condition of HCC patients [ 29 ]. However, there are still no global accepted guidelines for TACE treatment and the clinical outcomes vary among different individuals [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma

Quan

Li²,

Zhu

et al. 2021

Lipids Health Dis

View full text Add to dashboard Cite

Background This study aimed to explore the effect of inhibiting the Hippo/Yes-associated protein (YAP) signaling pathway on the outcomes of transcatheter arterial chemoembolization (TACE) in treating transplanted hepatocellular carcinoma (HCC). Methods A transplanted HCC rat model was established. Then, rats were randomly divided into four groups: Sham, TACE, verteporfin (inhibitor of Hippo/YAP), and TACE+verteporfin. Lent-OE-YAP was transfected into rats to overexpress YAP in vivo. After treatments, morphological changes, tumor weight, and the overall survival of rats in different groups were analyzed. Real-time PCR, immunohistochemistry staining, and Western blotting were used to determine the expression of factors related to the Hippo/YAP signaling pathway. Results Tumor weight and tissue lesions in the TACE and verteporfin groups were significantly reduced compared with the Sham group. Verteporfin significantly decreased tumor weight after TACE treatment. In addition, verteporfin significantly improved the overall survival of rats with transplanted HCC after TACE treatment. Compared with the Sham group, both TACE and verteporfin groups exhibited significantly decreased expression of macrophage-stimulating (MST)1, MST2, long-acting thyroid stimulator 1, transcriptional co-activator with PDZ-binding motif (TAZ), Yes-associated protein (YAP), TEA domain transcription factor (TEAD)1, TEAD2, TEAD3, and TEAD4. TACE plus verteporfin significantly enhanced the downregulation of effectors in the Hippo/YAP signaling pathway and decreased tumor size, while the overexpression of YAP exerted opposite effects. Conclusion The inhibition of the Hippo/YAP signaling pathway via verteporfin significantly improved the outcomes of TACE in treating transplanted HCC.

show abstract

Section: Discussionmentioning

confidence: 99%